Publication: npj Vaccines
By: Christian Garde, Michail A. Pavlidis, Pablo Garces, Emma J. Lange, Sri H. Ramarathinam, Mateo Sokač, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J. Birkbak, Jens V. Kringelum, Birgitte Rønø, Anthony W. Purcell & Thomas Trolle

In this interview, our CEO, Christian Kanstrup, walks you through Evaxion’s vision— Decoding the human immune system to develop novel vaccines for cancer and infectious diseases with our AI-Immunology™ platform.

Our Chief Executive Officer, Christian Kanstrup, and Chief Scientific Officer, Birgitte Rønø, had the pleasure yesterday of presenting our AI-Immunology platform, pipeline and strategy in conversation with Ramakanth Swayampakula, Senior Healthcare Analyst at H.C. Wainwright & Co., LLC.

In our latest interview on the BigBiz Show, we dive into: 

• Our vision to utilize AI to address serious unmet medical need and allow people to live healthier lives
• The latest advancements in EVX-01, currently in phase 2 of clinical development
• How our strategic partnership with MSD supports groundbreaking innovation in infectious disease therapies 
• The transformative potential of personalized cancer vaccines, which could target multiple solid tumors 

Are you eager to deep-dive into Evaxion's business? Download our company presentation.

AI-designed cancer vaccines: antigens from the dark genome are promising cancer vaccine targets

In this episode of the Big Biz Show, our CEO, Christian Kanstrup, shares the intriguing story of Evaxion and how the company, rooted in machine learning and advanced computational methods, emerged as one of the very few AI-first companies. Since the inception in 2008, Evaxion have developed a unique and strongly validated AI-Immunology™ platform that, as Christian explains it, positions us at the forefront of using AI to discover, design, and develop novel vaccine candidates for cancer and infectious diseases. 

At the LSX - partnering for Life Science eXecutives congress, Director of Immuno-Oncology & Preclinical Development, Stine Friis, shared Evaxion's recent achievements on large pharma deals and the promising data from our Phase 2 personalized cancer vaccine trial, highlighting the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets.

In this episode of the Big Biz Show, our CEO, Christian Kanstrup, delves into the details of the recently announced partnership for vaccine development with MSD, which expands the companies’ existing collaboration and brings significant value to Evaxion.

Advancing Vaccine Development through Precise AI-driven Prediction of Protective Antigens.